Bayer is acquiring eye disease drug developer Perfuse Therapeutics for up to $2.45 billion May 06, 2026 · Cris Tolomia Bayer will pay $300 million upfront, with the remainder tied to development, regulatory, and commercial milestones Read more »
.png?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
